Changes in Invasive Breast Carcinomas after Neoadjuvant Chemotherapy Can Influence Adjuvant Therapeutic Decisions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC) and influence the patients’ overall survival time (OS). We aimed to identify IBC changes after NACT and their association with OS.Materials and Methods IBC data in pre- and post-NACT samples of 86 patients were evaluated and associated with OS.Results Post-NACT tumors changed nuclear pleomorphism score (p=0.025); mitotic count (p=0.002); % of tumor-infiltrating inflammatory cells (p=0.016); presence of <i>in situ</i> carcinoma (p=0.001) and lymphovascular invasion (LVI; p=0.002); expression of estrogen (p=0.003), progesterone receptors (PR; p=0.019), and Ki67 (p=0.003). Immunohistochemical (IHC) profile changed in 26 tumors (30.2%, p=0.050). Higher risk of death was significatively associated with initial tumor histological grade III (hazard ratio [HR], 2.94), high nuclear pleomorphism (HR, 2.53), high Ki67 index (HR, 2.47), post-NACT presence of LVI (HR, 1.90), luminal B–like profile (HR, 2.58), pre- (HR, 2.26) and post-NACT intermediate mitotic count (HR, 2.12), pre- (HR, 4.45) and post-NACT triple-negative IHC profile (HR, 4.52). On the other hand, lower risk of death was significative associated with pre- (HR, 0.35) and post-NACT (HR, 0.39) estrogen receptor–positive, and pre- (HR, 0.37) and post-NACT (HR, 0.57) PR-positive. Changes in IHC profile were associated with longer OS (p=0.050). In multivariate analysis, pre-NACT grade III tumors and pre-NACT and post-NACT triple negative IHC profile proved to be independent factors for shorter OS.Conclusion NACT can change tumor characteristics and biomarkers and impact on OS; therefore, they should be reassessed on residual samples to improve therapeutic decisions.
Abstract
Purpose Neoadjuvant chemotherapy (NACT) can change invasive breast carcinomas (IBC) and influence the patients’ overall survival time (OS). We aimed to identify IBC changes after NACT and their association with OS.Materials and Methods IBC data in pre- and post-NACT samples of 86 patients were evaluated and associated with OS.Results Post-NACT tumors changed nuclear pleomorphism score (p=0.025); mitotic count (p=0.002); % of tumor-infiltrating inflammatory cells (p=0.016); presence of <i>in situ</i> carcinoma (p=0.001) and lymphovascular invasion (LVI; p=0.002); expression of estrogen (p=0.003), progesterone receptors (PR; p=0.019), and Ki67 (p=0.003). Immunohistochemical (IHC) profile changed in 26 tumors (30.2%, p=0.050). Higher risk of death was significatively associated with initial tumor histological grade III (hazard ratio [HR], 2.94), high nuclear pleomorphism (HR, 2.53), high Ki67 index (HR, 2.47), post-NACT presence of LVI (HR, 1.90), luminal B–like profile (HR, 2.58), pre- (HR, 2.26) and post-NACT intermediate mitotic count (HR, 2.12), pre- (HR, 4.45) and post-NACT triple-negative IHC profile (HR, 4.52). On the other hand, lower risk of death was significative associated with pre- (HR, 0.35) and post-NACT (HR, 0.39) estrogen receptor–positive, and pre- (HR, 0.37) and post-NACT (HR, 0.57) PR-positive. Changes in IHC profile were associated with longer OS (p=0.050). In multivariate analysis, pre-NACT grade III tumors and pre-NACT and post-NACT triple negative IHC profile proved to be independent factors for shorter OS.Conclusion NACT can change tumor characteristics and biomarkers and impact on OS; therefore, they should be reassessed on residual samples to improve therapeutic decisions.
참고문헌 (29)
- Reddy OL, "Breast cancer biomarker changes after neoadjuvant chemotherapy : a single institution experience and literature review", Clin Oncol, 2, pp.1245~ (2017)
- Chen Y, "Impact of hor mone receptor, HER2, and Ki-67 status conversions on sur vival after neoadjuvant chemotherapy in breast cancer pati ents : a retrospective study", Ann Transl Med, 10, pp.93~ (2022)
- Al-Saleh K, "Prognostic significance of estrogen, progesterone and HER2 receptors’ status conversion following neoadju vant chemotherapy in patients with locally advanced breast cancer : Results from a tertiary Cancer Center in Saudi Arabia", PLoS One, 16, pp.e0247802~ (2021)
- Candas G, "Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast can cer", Ecancermedicalscience, 15, pp.1162~ (2021)
- Yang L, "Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemother apy", World J Surg Oncol, 16, pp.51~ (2018)
- Mittendorf EA, "Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy", J Clin Oncol, 29, pp.1956~1962 (2011)
- Niikura N, "Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21, 755 patients from the Japanese breast cancer registry", Ann Oncol, 27, pp.480~487 (2016)
- Shaaban AM, "Receptor status after neoadju vant therapy of breast cancer : significance and implications", Pathobiology, 89, pp.297~308 (2022)
- Van Poznak C, "Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 33, pp.2695~2704 (2015)
- Katayama A, "Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer", Mod Pathol, 34, pp.1271~1281 (2021)
- "Joint Ordinance No. 5, APRIL 18, 2019. Diag nostic and therapeutic guidelines for breast carcinoma" (2019)[URL]
- WHO Classification of Tumours Editorial Board, "Breast tumours: WHO classification of tumours", pp.84~92 (2020), IARC Press
- Elston CW, "Pathological prognostic factors in brest cancer. I. The value of histological grade in breast cancer : experience from a large study with long-term follow-up", His topathology, 19, pp.403~410 (1991)
- Amin MB, "AJCC cancer staging manual", pp.211~212 (2017), Springer
- Allison KH, "Estrogen and progesterone receptor testing in breast cancer : American Society of Clini cal Oncology", College of American Pathologists guideline update, 2020, pp.144, 545~563
- Wolff AC, "Human epidermal growth factor receptor 2testing in breast cancer : American Society of Clinical Oncol ogy", College of American Pathologists clinical practice guide line focused update, 2018, pp.142, 1364~1382
- Curigliano G, "Highlights from the 13th St Gallen International Breast Can cer Conference 2013", Ecancermedicalscience, 7, pp.299~ (2013)
- WHO Classification of Tumours Editorial Board, "Breast tumours: WHO classification of tumours", pp.356~ (2019), IARC Press
- Tokuda E, "Differences in Ki67 expressions between pre-and post-neoadjuvant chemotherapy specimens might pre dict early recurrence of breast cancer", Hum Pathol, 63, pp.405~ (2017)
- Coiro S, "Biomarkers changes after neoadjuvant chemotherapy in breast cancer : a seven-year single institution experience", Diagnostics(Basel), 11, pp.2249~ (2021)
- Wang Y, "Ki67index changes and tumor-infiltrating lymphocyte levels impact the prognosis of triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy", Front Oncol, 11, pp.668610~ (2021)
- Chatterjee S, "Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers : do pre-NACT ER", PR status act as better prognosticators?, 2015, pp.7, 381~388
- Bossuyt V, "Invasive carcinoma of the breast in the setting of neoadjuvant therapy: histopathology reporting guide", International Collaboration on Cancer Reporting, ~ (2023)
- Sethi D, "Histo pathologic changes following neoadjuvant chemotherapy in locally advanced breast cancer", Indian J Cancer, 50, pp.58~64 (2013)
- Honkoop AH, "Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer", Am J Clin Pathol, 107, pp.211~218 (1997)
- Calhoun BC, "Core needle biopsy of the breast : an evaluation of contemporary data", Surg Pathol Clin, 11, pp.1~16 (2018)
- Ahmeidat H, "Non-histopathological parameters associated with upgrade of breast tumours yielding a core biopsy report of histological grade 2 ductal no special type to grade 3 on exci sion", Eur J Surg Oncol, 44, pp.1720~1724 (2018)
- Cha YJ, "Com parison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens : a retrospective analysis", Breast Cancer Res Treat, 171, pp.295~302 (2018)
- Balabram D, "Survival of patients with operable breast cancer(Stages I-III)at a Brazilian public hos pital : a closer look into cause-specific mortality", BMC Cancer, 13, pp.434~ (2013)